Half-year report · HY
9273.TEDINET S100XK39
Period2025-07-01 → 2025-12-31
Filed2026-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.7bn | 2025-07-01 → 2025-12-31 | Cons. | Net sales |
| Revenue | ¥23.3bn | 2024-07-01 → 2025-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.3bn | 2024-07-01 → 2024-12-31 | Cons. | Net sales |
| Operating income | ¥3.2bn | 2025-07-01 → 2025-12-31 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2025-07-01 → 2025-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.4bn | 2024-07-01 → 2025-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.1bn | 2025-07-01 → 2025-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2025-07-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2024-07-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2025-07-01 → 2025-12-31 | Cons. | Profit loss |
| Net income | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss |
| Total assets | ¥36.5bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥36.1bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥33.6bn | at 2024-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.0bn | at 2025-12-31 | Cons. | Liabilities |
| Total liabilities | ¥8.0bn | at 2025-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥29.6bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥28.1bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2024-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.2bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.9bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.0bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.7bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.8bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.2bn | at 2024-06-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥360m | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.8bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.3bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.7bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥829m | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥939m | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥738m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥49.53 | 2025-07-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥86.38 | 2024-07-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.66 | 2024-07-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 80.9% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.9% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.1% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-07-01 → 2025-12-31 | −¥649m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-07-01 → 2025-12-31 | −¥649m |
| Reconciling Itemsreconciling | segment profit | 2025-07-01 → 2025-12-31 | ¥46m |
| Drug Substance Sales Businessreportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥8.5bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥7.8bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥649m |
| Drug Substance Sales Businessreportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥1.8bn |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥4.8bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥4.8bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥1.3bn |
| —segment total | revenue | 2025-07-01 → 2025-12-31 | ¥13.3bn |
| —segment total | revenue external | 2025-07-01 → 2025-12-31 | ¥12.7bn |
| —segment total | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥649m |
| —segment total | segment profit | 2025-07-01 → 2025-12-31 | ¥3.1bn |
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2024-12-31 | ¥81m |
| Drug Substance Sales Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥8.0bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥7.4bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| Drug Substance Sales Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.6bn |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.4bn |
| —segment total | revenue | 2024-07-01 → 2024-12-31 | ¥12.9bn |
| —segment total | revenue external | 2024-07-01 → 2024-12-31 | ¥12.3bn |
| —segment total | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| —segment total | segment profit | 2024-07-01 → 2024-12-31 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 495
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | InterimInstant_No2MajorShareholdersMember | 4600000 | |
| Shareholding ratio | InterimInstant_No2MajorShareholdersMember | 0.1092 | |
| Number of shares held | InterimInstant_No3MajorShareholdersMember | 2108000 | |
| Shareholding ratio | InterimInstant_No3MajorShareholdersMember | 0.0501 | |
| Number of shares held | InterimInstant_No4MajorShareholdersMember | 1582000 | |
| Shareholding ratio | InterimInstant_No4MajorShareholdersMember | 0.0376 | |
| Number of shares held | InterimInstant_No5MajorShareholdersMember | 1140000 | |
| Shareholding ratio | InterimInstant_No5MajorShareholdersMember | 0.0271 | |
| Number of shares held | InterimInstant_No6MajorShareholdersMember | 937000 | |
| Shareholding ratio | InterimInstant_No6MajorShareholdersMember | 0.0223 | |
| Number of shares held | InterimInstant_No7MajorShareholdersMember | 927000 | |
| Shareholding ratio | InterimInstant_No7MajorShareholdersMember | 0.0220 | |
| Number of shares held | InterimInstant_No8MajorShareholdersMember | 804000 | |
| Shareholding ratio | InterimInstant_No8MajorShareholdersMember | 0.0191 | |
| Number of shares held | InterimInstant_No9MajorShareholdersMember | 694000 | |
| Shareholding ratio | InterimInstant_No9MajorShareholdersMember | 0.0165 | |
| Number of shares held | InterimInstant_No10MajorShareholdersMember | 487000 | |
| Shareholding ratio | InterimInstant_No10MajorShareholdersMember | 0.0116 | |
| Number of shares held | InterimInstant | 31111000 | |
| Shareholding ratio | InterimInstant | 0.7387 | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 1400 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 42094200 | |
| Number of voting rights issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 420942 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | 24380 | |
| Number of shares issued shares voting rights | InterimInstant | 42119980 | |
| Number of voting rights issued shares voting rights | InterimInstant | 420942 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row1Member | 1400 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row1Member | 1400 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row1Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | InterimInstant | 1400 | |
| Number of shares held in others names treasury shares etc | InterimInstant | － | |
| Total number of shares held treasury shares etc | InterimInstant | 1400 | |
| Shareholding ratio treasury shares etc | InterimInstant | 0.0000 | |
| Cash and deposits | Prior1YearInstant | 14919028000 | JPY |
| Cash and deposits | InterimInstant | 13164786000 | JPY |
| Notes and accounts receivable trade | Prior1YearInstant | 3575127000 | JPY |
| Notes and accounts receivable trade | InterimInstant | 5219086000 | JPY |
| Electronically recorded monetary claims operating ca | Prior1YearInstant | 4546823000 | JPY |
| Electronically recorded monetary claims operating ca | InterimInstant | 5090284000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 2124094000 | JPY |
| Merchandise and finished goods | InterimInstant | 2317275000 | JPY |
| Work in process | Prior1YearInstant | 540924000 | JPY |
| Work in process | InterimInstant | 447808000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 599763000 | JPY |
| Raw materials and supplies | InterimInstant | 669369000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |